Eton Pharmaceuticals (ETON) Gross Margin (2019 - 2026)

Eton Pharmaceuticals has disclosed Gross Margin across 8 years of filings, most recently posting 67.61% for Q2 2026.

• In Q2 2026, Gross Margin rose 461.0% year-over-year to 67.61%; the TTM figure through Jun 2026 stood at 58.14% (down 126.0% YoY), while the FY2025 annual figure was 53.46%, down 655.0% from the prior year.
• Gross Margin came in at 67.61% for Q2 2026 at Eton Pharmaceuticals, up from 61.56% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 92.26% in Q2 2022 to a low of 34.97% in Q3 2025.
• Average Gross Margin over 5 years is 63.09%, with a median of 62.65% recorded in 2023.
• Year-over-year, Gross Margin surged 4708 bps in 2022 and plunged 2607 bps in 2025.
• Over 5 years, Gross Margin stood at 74.84% in 2022, then tumbled by 34 bps to 49.64% in 2023, then advanced by 12 bps to 55.6% in 2024, then climbed by 11 bps to 61.56% in 2025, then advanced by 10 bps to 67.61% in 2026.
• Per Business Quant data, the three most recent Gross Margin figures were 67.61% in Q2 2026, 61.56% in Q4 2025, and 34.97% in Q3 2025.